American Society of Hematology 2020 Podcast Collection: FL and DLBCL

Abstract

Victoria Glasson (VG): Managing Editor of Advances in Therapy Chris Fox (CF): Consultant hematologist, Nottingham University Hospitals NHS Trust Wendy Osbourne (WO): Consultant hematologist, Freeman Hospital, Newcastle upon Tyne Hospital NHS Foundation Trust VG: Hello and welcome to the Adis Rapid? podcast series. We are bringing you a selection of podcasts covering the American Society of Hematology (ASH) 2020 conference, discussing the highlights of the data released. Today’s podcast will be focusing on follicular lymphoma (FL) and diffuse large B cell lymphoma (DLBCL), focused on CAR (chimeric antigen receptor)-T cell therapies and the data presented at the ASH conference. Speaking to us today is Dr. Christopher Paul Fox, consultant hematologist at Nottingham University Hospitals NHS Trust, honorary clinical associate professor at the University of Nottingham, and also chair of the Aggressive Lymphoma Group of the NCRI (National Cancer Research Institute). He is joined today by Dr. Wendy Osborne, consultant hematologist at the Freeman Hospital, Newcastle upon Tyne Hospital NHS Foundation Trust, and a fellow member of the NCRI clinical subgroups looking at high-grade, Hodgkin, and T cell lymphomas. Thank you so much for joining us today, Chris and Wendy. You are going to take us through your top highlights of the FL and DLBCL data that was released at the ASH conference and the implications of this data on future developments. A lot of important research was released at the conference, and we’re going to focus mainly on CAR-T cell therapies. CF: Thank you, Victoria, for the introduction and the opportunity to talk about some really interesting data on the CAR-T cell therapies that we saw presented at the ASH 2020 meeting, which is obviously a virtual meeting this year. But it worked really well. It’s a pleasure to have my colleague from Newcastle, Dr. Wendy Osborne, with me this evening. Wendy has, just to embarrass her slightly, she has a wealth of experience in both the delivery of CAR-T cell therapy and also in ongoing early phase trials, one of which we will Supplementary Information The online version contains supplementary material available at https:// doi.org/10.1007/s12325-021-01679-w.